ALYFTREK modulator approved in the United States, United Kingdom, European Union and Canada
ALYFTREK modulator approved in the United States, United Kingdom, European Union and Canada
- Cystic fibrosis patients receive triple therapy medication free of charge for the first time
- Minsa finalized the acquisition of high-cost medication to improve the quality of life of patients with cystic fibrosis
- ALYFTREK modulator approved in the United States, United Kingdom, European Union and Canada
- Approval of Law 29698 on Rare and Orphan Diseases: Law that declares the treatment of people suffering from rare or orphan diseases to be of National Interest and preferential attention.
- Approval of Law 31738: LAW THAT MODIFIES LAW 29698 LAW THAT DECLARES THE TREATMENT OF PEOPLE SUFFERING FROM RARE OR ORPHAN DISEASES TO BE OF NATIONAL INTEREST AND PREFERENTIAL ATTENTION